Thank you, Dave.
the on our to come it I'll my consumer the businesses. of first end relates me unit, Again, the to let Rx As business the Pharmaceuticals. to half near have I'll company's the only revenue first touch we and newly efforts core remarks. health XX, February acquired consumer the million. COVID-XX prepared Innovus consumer back of was and for health on $X.XX operations, closed speak which this quarter's acquisition segment
the for business key of rationalize about quarter G&A already functions excited ahead. and the We're this this segment aim and a realizing was getting some to forward looking many we're overlapping unit profitability. to with begun to we've solid also of the segments synergies consumer It growth
due relatively enabled has e-commerce to and marketing segment COVID-XX. to direct-to-consumer of our with Consumer blend disruption of continue business unique Innovus' Importantly, the Health little
While we impact, it we'd expect do some expect modest. be to relatively
of staying for team Innovus Regoxidine, Consumer ever, course home The and Rogaine. product in early retail U.S. sales This with with units performance approximately been team be than virus, for me, has the million to for was treatment Health a People, hair a sold XX the that important launch strong annually. more is women due in loss so function men competes to business. the the consumer e-commerce our An continued weeks. product the particular category with are health has the excuse in pleased
supplements identify to business, segments and The strategy more to similar. and in continue apply track out Health preparing I health new to the franchise address the OTC sharing product large quarter forward come selection products we is For and business launch We in consumer coming are to product the market. markets products and in both to look Consumer build the are new these over consumer products competing needs. health novel to medicines for plan on right they launches. significant order as the very patient
prescription supplement full more The short-term quarter And we newly should prescription of COVID our rapid also a Rx our are revenue. COVID a expected quarter prescription seeing portfolio. productive a while test our with first sales, business impact the than sales on and expanded had
to that clinical had I'll that though, speak note I important Natesto recent Before an development.
demonstrating testosterone April. Natesto therapies X the Urology Natesto will this hypogonadal data this clinical and to is announced other fertility treated resonating clinical months. men replacement we million QX were after data and further in We in The Natesto reputable community nearly to stands Journal urology Just separate of prescription with of from in in believe peer-reviewed research the six maintenance that continue of the the in category. for published publication resonate
We Turning ER and the starting continuing portfolio. from Rx revenue solid late into notable saw as products the we to growth now Karbinal we prescription mix. numerous of contributing rest the the highlight, year revenue season. to spring One calendar contribution specific across the had portfolio last have Rx allergy
growth solid see position We are our the Rx with business we about to ahead. excited respect and
our March Despite of fact the due field COVID, they have to to impact. we've have the since had able most late out reps the been of still
our this Importantly, as using selling have their we've enhanced company and time a reps skills their sharpen product been knowledge. to
commercial training. Our considerable time important developing team sales leadership has spent
learning have sales physician accounts. successes the great customer some access their virtual knowledge. rest and creative have creative contact ways The a refining the They job conducting also as maintaining been this have had reported with meetings have find and territory field important while and remained and we've getting prescribers. done Reps new with great doing from and reps prescribers their some to busy been and
our prudent We're in personal in effective are way and states safe to but lives, some semblance ease of and back how normalcy now in get be to up. making and company our all the professional to starting back as into municipalities we and calls a back will reps anxious
with distancing purchasing and rapid we've the selling being our With warehousing efforts, disruption. shipping place. healthcare measures in selling is Also put COVID the minimal remotely. COVID of and social test Nearly been have test has done accounts effectively all been rapid test respect to done had servicing the safe
So with important high have the COVID-XX our I respect COVID interest various updates. to some and projects, in
that received As we've immediately into And Colorado and a we released U.S. to COVID-XX initial today have began shipment of warehouse inform for pleased number we early selling. tests previously announced we've now rapid in distributing April into since that of I'm tests and XXX,XXX distribution. are received our an large you
fact experience for going and now a cleared obvious that to receiving We by to the had tests been the are are by made were the actually did that in expecting here product, I'm that tests while these tests the we say delay customers, out are here these the China. export perhaps fact happy is and indeed
So rapid tests tests our the More forward. we in steady and are are expect warehouse. coming going supply tests a of
the on touch I'll opportunity. remarks, device prepared Healight my in medical Finally,
began have novel we Cedars in at to Center by with the The MAST XX, developed a an announced worldwide Angeles. onset via led Pimentel, program infections we the the administered COVID-XX in Medical pivoted As novel have the April using back UV signed treat as of Cedars-Sinai and on exclusive the light research crisis, Dr. treatment the for Mark to license researchers agreement XXXX approach Los COVID potential The a Healight catheter. group study with the a virus.
out Significant team to it Very has to MAST relates with device discussions Aytu with preclinical after finalize been recently, Devices Medical team development. the with research results as Sterling devices the and has carried both been with FDA in the the observed. COBIT have engaged in promising
this devices we're human about on utility treatment as for we clarity and FDA such in conditions, ventilator expect pneumonia. about forward our path devices potential scale move of for device, small the We other clarity, the seeking to associated enthusiastic into We're COVID are use. collectively receiving from such excited upon the for and production potential
XXX,XXX of flu year. influenza are between U.S. ventilator alone. caused this associated And season in U.S. There XXX,XXX in and cases the past the XXX,XXX pneumonia hospitalizations each over
for strong to it and transformational quarter our was wrap So the prepared up company. comments, a
kit highest summarize, a We history. in test quantity received. company's quarterly to the distribution tests recorded the fight of through entered with we've just So now COVID-XX large agreements, our and revenue two
up Innovus common We We cash. our opportunity ended shares with finally with substantially table into Rx all quarter we're Healight. $XX stock, moving in novel preferred We acquisition. as over million and cap quarter business. having forward with closed a We the first the converted on now full completed a combined our cleaned
With you call we'll from the call today's questions analysts. that, and joining thank for for now open up the
